Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
prostatic hyperplasia/rasvumus
Link salvestatakse lõikelauale
Leht 1 alates 221 tulemused
Effect of obesity on prostatic hyperplasia: its relation to sex steroid levels.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
In 68 men with benign prostatic hyperplasia, we evaluated the association between obesity and prostatic enlargement, as well as changes in serum levels of oestradiol, testosterone, dihydroepiandrosterone and dihydroepiandrosterone sulphate. Despite the larger adenomas, no increase in the symptom
[Relation between benign prostatic hyperplasia and obesity and estrogen].
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
OBJECTIVE
There have been few reports on correlations between resection volume of benign prostatic hyperplasia, body mass index (BMI) and estrogen. This study was undertaken to evaluate the correlations.
METHODS
In this study, we considered 50 patients who had benign prostatic hyperplasia (BPH) and
[The role of obesity in the pathogenesis of benign prostatic hyperplasia].
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The pathophysiological role of obesity as one of the most significant and actual metabolic non-infectious diseases and the key component of the metabolic syndrome based on results of modern epidemiological and clinical-experimental studies is discussed in the review. General information on the
Age and Obesity Promote Methylation and Suppression of 5α-Reductase 2: Implications for Personalized Therapy of Benign Prostatic Hyperplasia.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
OBJECTIVE
In men with symptomatic benign prostatic hyperplasia 5α-reductase inhibitors are a main modality of treatment. More than 30% of men do not respond to the therapeutic effects of 5α-reductase inhibitors. We have found that a third of adult prostate samples do not express 5α-reductase type 2
Comparison of the clinical efficacy of medical treatment of symptomatic benign prostatic hyperplasia between normal and obese patients.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
We aimed to investigate the difference in efficacy of medical treatment of symptomatic benign prostatic hyperplasia (BPH) between normal and obese patients with BPH; obesity was determined by either body mass index (BMI) or waist circumference (WC). In this 12-week prospective observational study, a
Obesity in relation to prostate cancer risk: comparison with a population having benign prostatic hyperplasia.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
OBJECTIVE
To analyse the relationship between obesity and prostate cancer, when compared with men with benign prostatic hyperplasia (BPH).
METHODS
The records were reviewed of consecutive patients with histologically confirmed prostate cancer admitted for prostate surgery between January 1993 and
Toll-like receptor 9 regulates metabolic profile and contributes to obesity-induced benign prostatic hyperplasia in mice.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Effect of Serenoa Repens on Oxidative Stress, Inflammatory and Growth Factors in Obese Wistar Rats with Benign Prostatic Hyperplasia.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Serenoa repens has been widely used to treat benign prostatic hyperplasia and lower urinary tract symptoms; however, most of the studies have been conducted in individuals with normal weight and not obese. In this study, the effects of a lipidic extract of S. repens, in markers of oxidative stress,
Cigarette smoking, obesity, and benign prostatic hypertrophy: a prospective population-based study.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The authors examined the relation of smoking and obesity to surgically treated benign prostatic hypertrophy in a prospective study of white men aged 40-79 years who were first examined in 1972-1974 and were followed for an average of 12 years. After exclusion of those whose surgery preceded
Larger prostatic adenomas in obese men with no associated increase in obstructive uropathy.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
In 379 men less than age 75 years who underwent initial transurethral prostatectomy for benign prostatic hypertrophy specimen weights were compared with host ages, obesity, smoking habits and the presence of incidental cancer. Among 334 men 60 to 74 years old average specimen weights increased with
Lower urinary tract symptoms, benign prostatic hyperplasia, and obesity.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Obesity has emerged as a global public health challenge. During the past 20 years, there has been a dramatic increase in obesity in the United States. In 2007, only one state had a prevalence of obesity less than 20%. In this growing epidemic of national concern is an emerging relationship between
Central obesity as a risk factor for prostatic hyperplasia.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
OBJECTIVE
Obesity-related metabolic diseases may influence prostatic hyperplasia. This study examined the impact of obesity on prostate volume in men without overt obesity-related metabolic diseases.
METHODS
We recruited 146 men over the age of 40 years who did not have overt obesity-related
Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
OBJECTIVE
Benign prostatic hyperplasia is a highly prevalent disease in older men with substantial adverse effects on public health. Classic etiological paradigms for benign prostatic hyperplasia focus on nonmodifiable risk factors. However, obesity also potentially promotes benign prostatic
Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
OBJECTIVE
Benign prostatic hyperplasia is a highly prevalent disease in older men with substantial adverse effects on public health. Classic etiological paradigms for benign prostatic hyperplasia focus on nonmodifiable risk factors. However, obesity also potentially promotes benign prostatic
Effect of weight reduction on the severity of lower urinary tract symptoms in obese male patients with benign prostatic hyperplasia: a randomized controlled trial.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
OBJECTIVE
We assessed whether weight reduction is an effective intervention for the management of lower urinary tract symptoms (LUTS) and investigated the relationship between obesity and LUTS.
METHODS
This was a prospective randomized controlled trial that enrolled obese men older than 50 years
Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus
- Töötab 55 keeles
- Taimsed ravimid, mida toetab teadus
- Maitsetaimede äratundmine pildi järgi
- Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
- Lugege oma otsinguga seotud teaduspublikatsioone
- Otsige ravimtaimi nende mõju järgi
- Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega
Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel
